SG93776A1 - Peptides, fragments thereof, and preparation of compositions therefrom - Google Patents

Peptides, fragments thereof, and preparation of compositions therefrom

Info

Publication number
SG93776A1
SG93776A1 SG9603410A SG1996003410A SG93776A1 SG 93776 A1 SG93776 A1 SG 93776A1 SG 9603410 A SG9603410 A SG 9603410A SG 1996003410 A SG1996003410 A SG 1996003410A SG 93776 A1 SG93776 A1 SG 93776A1
Authority
SG
Singapore
Prior art keywords
peptide
high performance
liquid chromatography
performance liquid
phase high
Prior art date
Application number
SG9603410A
Other languages
English (en)
Inventor
James Smith Cooper Garth
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SG93776A1 publication Critical patent/SG93776A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Socks And Pantyhose (AREA)
SG9603410A 1987-08-26 1988-08-26 Peptides, fragments thereof, and preparation of compositions therefrom SG93776A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878720115A GB8720115D0 (en) 1987-08-26 1987-08-26 Treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
SG93776A1 true SG93776A1 (en) 2003-01-21

Family

ID=10622830

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9603410A SG93776A1 (en) 1987-08-26 1988-08-26 Peptides, fragments thereof, and preparation of compositions therefrom

Country Status (14)

Country Link
US (2) US5124314A (fr)
EP (2) EP0309100B1 (fr)
JP (1) JP2828250B2 (fr)
AT (1) ATE155688T1 (fr)
AU (1) AU634954B2 (fr)
CA (1) CA1341060C (fr)
DE (1) DE3855970T2 (fr)
DK (1) DK473888A (fr)
ES (1) ES2106721T3 (fr)
FI (1) FI883936A7 (fr)
GB (1) GB8720115D0 (fr)
GR (1) GR3024705T3 (fr)
NO (1) NO883828L (fr)
SG (1) SG93776A1 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298605A (en) * 1986-10-08 1994-03-29 Regents Of The University Of Minnesota Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5405831A (en) * 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
JP2533726Y2 (ja) * 1990-07-23 1997-04-23 船井電機株式会社 記録再生機器
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5527771A (en) * 1991-01-10 1996-06-18 Amylin Pharmaceuticals, Inc. Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
WO1992015317A1 (fr) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Preparation synthetique d'amyline et d'analogues d'amyline
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0503827A1 (fr) * 1991-03-15 1992-09-16 Pfizer Inc. Utilisation d'amyline et de la peptide apparenté aux gènes de la calcitonine et les antagonistes
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
SG44838A1 (en) * 1991-05-24 1997-12-19 Amylin Pharmaceuticals Inc Insulin and amylin containing composition for the treatment of insulin deficient mammals
SG49239A1 (en) * 1991-05-24 1998-05-18 Amylin Pharmaceuticals Inc Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CA2100745C (fr) * 1991-11-19 2007-07-31 Laura S. L. Gaeta Peptides agonistes de l'amyline et leur utilisation
WO1993019774A1 (fr) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Composition contenant de l'amyline et eventuellement de l'insuline pour le traitement de l'anorexie et de maladies apparentees
ATE171951T1 (de) * 1992-08-06 1998-10-15 Pfizer Amylin muteine
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5545672A (en) * 1993-02-11 1996-08-13 The University Of Texas System Treatment of insulin resistance and type 2 diabetes mellitus with a thiol protease inhibitor
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
WO1996002269A1 (fr) * 1994-07-13 1996-02-01 Auckland Uniservices Limited Procede therapeutique et composes associes
ES2285707T3 (es) 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
WO1997026321A2 (fr) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Expression recombinee de proteines a partir de lignees cellulaires secretoires
WO1997041090A1 (fr) 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Composes servant a declencher l'activite d'un recepteur d'ions inorganiques
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
EP1051141A4 (fr) * 1998-01-09 2001-05-23 Amylin Pharmaceuticals Inc Compositions pharmaceutiques a agoniste d'amyline, contenant de l'insuline
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000078805A1 (fr) * 1999-06-18 2000-12-28 Protemix Corporation Limited Peptide ayant une fonctionnalite preptine
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
WO2001000223A2 (fr) * 1999-06-25 2001-01-04 Minimed Inc. Therapie anti diabete a agents multiples
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2422911A1 (fr) * 2000-09-19 2002-03-28 Paul Fraser Nouveaux inhibiteurs de la formation de fibrilles d'iapp et utilisations associees
WO2002067969A2 (fr) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Compositions d'insuline stabilisees
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP1461068A4 (fr) * 2001-11-26 2006-03-29 Protemix Corp Ltd Procedes et compositions pour normaliser les niveaux lipidiques dans les tissus mammaliens
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
ATE412421T1 (de) * 2002-01-08 2008-11-15 Amylin Pharmaceuticals Inc Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
WO2004037168A2 (fr) * 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Traitement de la pancreatite avec de l'amyline
EP1631308B1 (fr) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
RU2360671C2 (ru) * 2003-07-01 2009-07-10 Эссентис Аб Применение альфа-кетоглутаровой кислоты для лечения недостаточности питания или состояния с высоким уровнем глюкозы в плазме
ATE471340T1 (de) * 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US20080032915A1 (en) * 2004-02-12 2008-02-07 Campina Nederland Holding B.V. Cysteine Rich Peptides for Improving Thiol Homeostasis
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
EP1996224B1 (fr) 2006-03-15 2012-11-07 Novo Nordisk A/S Melanges d'amyline et d'insuline
KR20100071985A (ko) * 2007-09-11 2010-06-29 몬도바이오테크 래보래토리즈 아게 치료제로서의 데펜신 펩티드의 용도
AU2008310076A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag CGRP as a therapeutic agent
EP2036539A1 (fr) 2007-09-11 2009-03-18 Novo Nordisk A/S Formulations stables d'amyline et ses analogues
CA2755068C (fr) 2009-03-12 2018-11-06 Keybioscience Ag Traitement du diabete et du syndrome metabolique
WO2011067283A1 (fr) 2009-12-01 2011-06-09 Novo Nordisk A/S Nouvelles peptidyl a-hydroxyglycine a-amide lyases
IL243355B2 (en) 2013-07-03 2024-10-01 Lundbeck Seattle Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
US10772556B2 (en) 2014-11-05 2020-09-15 Cláudio Afonso Ambrósio Method and system for monitoring and treating hypoglycemia
US10463717B2 (en) 2016-12-27 2019-11-05 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
JP7240004B2 (ja) 2017-07-27 2023-03-15 アドシア 少なくともヒトインスリンａ２１ｇおよび食事作用性グルカゴンサプレッサーを含む水溶液注射剤の形態の組成物
FR3082426A1 (fr) 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US20190275108A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
BR112020011479A2 (pt) 2017-12-07 2020-11-17 Adocia composições na forma de uma solução aquosa injetável caracterizada pelo fato de que compreende amilina, um agonista do receptor de amilina ou um análogo de amilina e um co-poliaminoácido
TWI813604B (zh) 2017-12-07 2023-09-01 法商阿道洽公司 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液
TW201938190A (zh) 2017-12-07 2019-10-01 法商阿道洽公司 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的ph 7之可注射溶液
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
EP3915572A1 (fr) 2020-05-29 2021-12-01 Adocia Composition pharmaceutique sous la forme d'une solution aqueuse injectable comprenant au moins un analogue de l'insuline à action rapide et un suppresseur de glucagon à action prandiale
EP3915571A1 (fr) 2020-05-29 2021-12-01 Adocia Composition pharmaceutique sous la forme d'une solution aqueuse injectable comprenant au moins un analogue de l'insuline à action rapide et un suppresseur de glucagon à action prandiale

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687839A (en) * 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
EP0263802A1 (fr) * 1986-10-08 1988-04-13 Per Westermark Composition contenant un polypeptide d'amyloide du pancréas et/ou d'anticorps de ce polypeptide et usage de cette composition
EP0270376A2 (fr) * 1986-12-04 1988-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Dérivés peptidiques liés au gène de la calcitonine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2141430B (en) * 1983-06-15 1987-01-21 Kingdon Craig R Peptides, pharmaceutical compositions, genes, vectors, host organisms, processes for their production and diagnostic reagents
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
GB8327346D0 (en) * 1983-10-12 1983-11-16 Morris H R Peptide
US4736023A (en) * 1983-12-23 1988-04-05 The Salk Institute For Biological Studies DNA encoding human CGRP
GB8407907D0 (en) * 1984-03-27 1984-05-02 Sandoz Ltd Organic compounds
EP0188400B1 (fr) * 1985-01-16 1992-07-08 Ciba-Geigy Ag Oligopeptides, les intermédiaires et leur procédé de préparation
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
US4697002A (en) * 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687839A (en) * 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
EP0263802A1 (fr) * 1986-10-08 1988-04-13 Per Westermark Composition contenant un polypeptide d'amyloide du pancréas et/ou d'anticorps de ce polypeptide et usage de cette composition
EP0270376A2 (fr) * 1986-12-04 1988-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Dérivés peptidiques liés au gène de la calcitonine

Also Published As

Publication number Publication date
GB8720115D0 (en) 1987-09-30
ATE155688T1 (de) 1997-08-15
FI883936A0 (fi) 1988-08-25
US5124314A (en) 1992-06-23
FI883936L (fi) 1989-02-27
DE3855970D1 (de) 1997-09-04
EP0309100A2 (fr) 1989-03-29
FI883936A7 (fi) 1989-02-27
HK1000934A1 (en) 1998-05-08
CA1341060C (fr) 2000-07-25
JPH0196137A (ja) 1989-04-14
US5641744A (en) 1997-06-24
EP0309100A3 (fr) 1991-04-03
NO883828L (no) 1989-02-27
EP0309100B1 (fr) 1997-07-23
NO883828D0 (no) 1988-08-26
JP2828250B2 (ja) 1998-11-25
ES2106721T3 (es) 1997-11-16
GR3024705T3 (en) 1997-12-31
DK473888D0 (da) 1988-08-25
EP0787741A1 (fr) 1997-08-06
DE3855970T2 (de) 1998-01-29
AU2157588A (en) 1989-07-20
AU634954B2 (en) 1993-03-11
DK473888A (da) 1989-04-05

Similar Documents

Publication Publication Date Title
SG93776A1 (en) Peptides, fragments thereof, and preparation of compositions therefrom
Shimizu et al. Proteolytic enzyme in porcine immature enamel
Sanger The chemistry of insulin
Takasaki et al. Sarafotoxins S6: several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart
SU849998A3 (ru) Способ получени циклических пептидов
KR100658961B1 (ko) 공유적으로 가교결합된 인슐린 이량체, 이를 포함하는 약제학적 조성물 및 진단 키트, 및 이의 제조방법
Chance Amino acid sequences of proinsulins and intermediates
HUT54213A (en) Process for the enzymatic removal of n-terminal sequence of proteins
DE10075019I2 (de) Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung.
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
RU98112109A (ru) Производное инсулина или его физиологически приемлемая соль, предшественник производного инсулина, днк-последовательность, кодирующая предшественник, вектор экспрессии, содержащий упомянутую днк-последовательность, субстрат, трансформированный упомянутым вектором экспрессии, и фармацевтическая композиция с понижающей, соответственно регулирующей уровень глюкозы в крови эффективностью
HUT63457A (en) Process for producing triarginine insulins
JPH06500311A (ja) ヒスチジン置換されたヒト成長ホルモン放出因子類縁体
ATE145241T1 (de) Polypeptid, das zur interaktion mit thrombin fähig ist
CA2208274A1 (fr) Analogues de peptide p227 et compositions pharmaceutiques comprenant ces analogues utilisees dans le traitement ou le diagnostic du diabete
TW275066B (fr)
Butler et al. Homologous regions of collagen α1 (I) and α1 (II) chains: Apparent clustering of variable and invariant amino acid residues
CA2041638A1 (fr) Produits de polynucleotide recombinants servant a fournir des secretions de pai-2
SAITOH et al. Further Fractionation of Basic Proline-Rich Peptides from Human Parotid Saliva and Complete Amino Acid Sequence of Basic Prolme-Rich Peptide PH
McDermott et al. Fe2+ oxidation of α-crystallin produces a 43,000 Da aggregate composed of A and B chains cross-linked by non-reducible covalent bonds
Fenger α-Melanocyte-stimulating-hormone precursors in the pig pituitary
Takahashi et al. The amino acid sequence of ribonuclease U1, a guanine-specific ribonuclease from the fungus Ustilago sphaerogena
Lopez-Trascasa et al. Isolation and characterization of a biologically active C2 derived oligopeptide
Ohta et al. The amino acid sequence of toxin D isolated from the venom of Indian cobra (Naja naja)
Saito et al. Sialoglycopeptides Isolated from Bovine. Aorta